Audrey's Life Science Meeting Picks for March 12, 2017 – May 2017
Complimentary Service of AudreysNetwork.com
March 12, 2017

****

UCSC Clinical Trials Course: March 13-17, 2017

Event: Clinical Trials Essentials: An Intensive One-Week Course
Event Dates: Monday March 13- Friday, March 17 2017
03/13/2017 - 8:00am
Event Location: UCSC Ext 3175 Bowers Avenue, Santa Clara

Event Description
The course benefits anyone working in the biopharmaceutical and medical device industries and the biomedical community who is interfacing with or conducting clinical research, including new clinical research associates and study coordinators; medical directors, physicians, nurses, pharmacists, and other health professionals; biomedical scientists; statisticians and database administrators; and business professionals.

****

Bio2Device Group, Tuesday Evening, March 14, 2017

Topic: "Brink of Catastrophe: Catching Addiction Early"
Speaker: David Deacon, CEO, DxRx Inc
Date and Time: Tuesday, March 14, 2017, 6:00 pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.Bio2DeviceGroup.org

Topic Description
One out of every ten Americans has a condition doctors call Alcohol Use Disorder or AUD. If you have AUD, your choices and activities begin to be changed by your drinking habits. With so many people affected, we should call AUD an epidemic. Instead, most people suffer in silence. Because of that silence, we get a very warped impression of alcoholism. A few late stage cases, like the derelicts passed out in the streets, are hyper-visible, while the millions of early stage cases are invisible. Yet people avoid treatment out of fear of being stigmatized for AUD, and it's all due to visibility bias.
Alcohol abuse disorder must be treated effectively like any other disease. It's not a disease of the willpower. It's a chronic condition that arises when your brain reward systems get "hijacked" by the addictive substance. Some people's neurotransmitter systems are more vulnerable than others, and the more vulnerable ones get locked into the addiction cycle. It is neurotransmitter malfunction that locks in the addiction, and studies show that neural system recovery can take most of a year, depending on severity. Like any addiction, alcoholism continues to get worse if left untreated.
Most people have only two choices of treatment modality today: Alcoholics Anonymous, a support group which is available everywhere but not very effective; and Rehab, a residential dry out approach which is effective near-term but impossible for most people to use. Given these choices, it should be no surprise that so few of the 34 million AUD sufferers get any kind of treatment at all. Out of the big six chronic diseases, AUD stands alone in that barely

7% get treated each year.
What I find most surprising is that effective medical treatment has been available for almost 25 years without being broadly adopted by the medical profession. I am referring to "Medication-Assisted Treatment" with naltrexone, which has been tested and shown effective in multiple clinical trials. Why is this treatment not widely available today? What does it take to make this treatment available to everyone? Can a technology-enabled medical service company break through the barriers?

Speaker Bio
David is an entrepreneurial leader who has built four successful startups as founder, member of the board, and line executive in product development, sales, and business development.
As entrepreneur, he developed multiple products leveraging technology to provide new customer value in telecom, diagnostics, and medical devices; as angel investor he has coached dozens of technology companies from concept into commercialization.
David's business leadership includes recognizing market shifts in time to pivot the business focus, hiring standout teams from CEO through Engineer, managing IP portfolios leading to 62 issued patents, and leading an international team for four years in Europe; raised $50 M from Tier-1 VCs and strategic partners; BS in Electrical Engineering, Massachusetts Institute of Technology and PhD in Physics, Stanford University.
****

WIB, Thursday Evening, March 16, 2017

Event: WIB-San Francisco Bay Area Women's History Month Event:
Leveraging Partnerships in the Growing Immuno-Oncology Space,
Date and Time: Thursday, March 16, 2017, 5:30 p.m. – 8:30 p.m. PST
Moderator: Stacy Feld, VP, Consumer Venture Investments & External Innovation, J&J Innovation - JJDC
Panelists: Julie Hambleton, MD, VP and Head of US Medical, Bristol-Myers Squibb
Sylvaine Cases, PhD, VP of Oncology Scientific Innovation, Janssen R&D and J&J Innovation;Jane Grogan, PhD, Head of Adaptive Tumor Immunity and Principal Scientist, Genentech
Registration Deadline
March 13, 2017
Location:JLABS @ SSF,329 Oyster Point Blvd., South San Francisco, CA 94080
Fees: Member - $25 and Nonmember-$55
Register at http://womeninbio.org/eventdetails.aspx?EventId=30876

Event Description
This event will feature women leading innovation, development, and growth through partnerships at life science companies. As biopharmaceutical companies seek to add novel candidates to their pipeline, immuno-oncology (pharmaceuticals that target the immune system to help fight cancer) has been an active area of focus for venture capital investment, partnerships, and collaborations in the life science sector.
Although the immuno-oncology space is still nascent, there has been a steady flow of collaborations announced across a diverse range of deal structures.
Panelists will share their perspectives, experience, and lessons learned in evaluating and implementing immuno-oncology partnerships. Come and be inspired by these women leading the way in the biotech industry!
Participants will:
- Hear about trends in immuno-oncology
- Listen to industry leaders describe critical factors for successful partnerships

- Learn about partnership resource needs and life cycle as well as examples of building from synergies
- Be exposed to various types of collaborations and lessons learned in evaluating and implementing these partnerships.

Learn more and register for this event.

****

CABS, Saturday Afternoon, March 18, 2017

Topic: "NGS for cancer and autoimmune diseases"
Date and Time: Saturday March 18, 2017 @1:30 pm - 4:00 pm
Location: Genentech Building 31, 1531 Grandview Drive South San Francisco CA, 94080
(Note venue change with added capacity and earlier check-in & networking start time)
Cost: free
1:30-2:00PM check-in, onsite registration and networking
2:00PM-4:00PM
Register at
http://www.cabsweb.org/events/2455515/NGS%20for%20cancer%20and%20autoimmune%20diseases/
Program Description
Presentations:

- ***Personalized health care for oncology*** by Craig Cummings, Associate Director, Oncology Biomarker Development, Genentech
- ***NGS application in immunology studies*** by Naibo Yang, Director, Immunogenetics, Complete Genomics Inc.

****

HBA, Monday Evening, March 20, 2017

Event: Fireside Chat: The Future of Medicine with Former NBC Medical Journalist Dr. Nancy Snyderman
Featured speakers: Nancy Snyderman, Consulting global health professor, former otolaryngologist, former chief medical editor, Stanford University; Jennifer Lovejoy, Chief science officer, Arivale; Ramji Srinivasan, Chief executive officer, Counsyl; Darren Brown, Executive vice president, employee benefits, ABD Insurance & Financial Services
Date and time: Monday, 20 March, 5:30PM - 8:30PM PST
Agenda
5:30 - 6:15 PM Registeration and networking
6:15 - 6:25 PM Opening remarks from the HBA
6:25 - 6:30 PM ABD Insurance remarks
6:30 - 6:35 PM Welcome remarks by Counsyl CEO and co-founder, Ramji Srinivasan
6:35 - 7:00 PM The science of wellness by Arivale, CSO Jennifer Lovejoy, PhD
7:00 - 7:45 PM Fireside chat with Dr. Nancy Snyderman
7:45 - 8:15 PM Q&A
8:15 - 8:30 PM Wrap up and closing
Location: Counsyl, 180 Kimball Way, South San Francisco, CA 94080
Registration information
Event is open to: HBA members and nonmembers
Early bird registration deadline: 1 March, 2017
Online registration deadline: 16 March, 2017

Onsite (walk-in) registration: Is allowed
Fees:

Registration Name	Price Level	Early Bird	Regular
1 - Regular registration	Member	$30.00	$40.00
1 - Regular registration	Non-Member	$45.00	$55.00
2 - Counsyl employee registration	Member	$25.00	$35.00
2 - Counsyl employee registration	Non-Member	$25.00	$35.00
3 - Arivale employee registration	Member	$25.00	$35.00
3 - Arivale employee registration	Non-Member	$25.00	$35.00
4 - ABD employee registration	Member	$25.00	$35.00
4 - ABD employee registration	Non-Member	$25.00	$35.00

Cancellations/refunds
Is this event refundable? Yes
If yes, requests must be submitted in writing to events@hbanet.org by 16 March, 2017; no refunds are available after this date.
Details and registration at
https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=37E161F6-32E7-E611-B295-0050569C00A7

Event contact
Parisha Dalia
408-306-1520

Learning objectives
1. Understand the mission and goals of new health tech companies entering the space around genetic screening and the science of wellness
2. Gain valuable insights into how today's big healthcare topics in patient advocacy, big data, wellness, genetic screening and drug pricing will affect patients and practitioners

Registration information
The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.
The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.
Event Description
Please join HBA San Francisco, along with sponsors Counsyl and Arivale for a lively discussion on how healthcare's biggest topics will affect doctors and patients in the future.

Hosted by Counsyl, a health technology company focused on genetic screening, you will hear from Ramji Srinivasan, CEO and co-founder, Counsyl, as well as Jennifer Lovejoy, PhD, CSO, Arivale, who will provide an overview into the science behind wellness. Then, for the main event, guests will enjoy a fireside chat with Dr. Nancy Snyderman, former medical journalist for NBC News. Nancy will draw on her three decades of experience as a head and

neck cancer surgeon and medical journalist to provide valuable insights into how the strides being made in wellness, patient advocacy, big data including next generation sequencing and drug pricing will affect the future practice of medicine.

You won't want to miss this unique opportunity to meet and hear from this group of talented and accomplished leaders in health, tech and medicine.
Special instructions: Parking available onsite.

****

EPPICon 2017, Saturday, March 25, 2017

Event: 11th Annual flagship event of EPPIC Global
Keynote Speakers: Ira Mellman, PhD (Genentech) and D. J. Patil (Chief Data Scientist, White House Office of Science and Technology)
Date and Time: Saturday, March 25, 2017,
8:00 AM: Registration open - Breakfast and Networking
9:00 AM: Opening / Plenary Keynote - Ira Mellman, PhD, Genentech
10:30 AM – 5:00 PM: Panels and Speakers
Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010
Registration online: $100
On-site Registration: $150
Student/Post Doc Registration Online: $75* (Valid student ID to be presented at Conference)
EPPIC Charter Members** / Sponsors** / Event Speakers**
(Registration includes food and beverage - breakfast, lunch, coffee breaks and evening reception)
* Student/Post Doc promo code "STCON17"
** Renew or Register with Code provided to you: Conference is complimentary
Register at
https://s07.123signup.com/servlet/SignUpMember?PG=1536045182300&P=15360451911431663100
Visit www.eppicon.org for more information

Event Description
Since 1998, EPPIC Global has been serving the San Francisco Bay Area life sciences community promoting entrepreneurship, networking, partnering, and mentoring. Join us to hear expert talks and panel discussions on

Immunotherapy, Bioinformatics and Diagnostics
If targeted therapies and personalized medicine revolutionized cancer treatment in the last decade, will Immunotherapy be the next big hope during the coming decade?
Have we finally got a handle on big data and where is Bioinformatics headed?
Ditto with regard to Biomarkers and Diagnostics?

Advances in cancer immunotherapy have generated enthusiasm across all fields of oncology. Complimentary/companion diagnostics along with predictive biomarkers are integral to improving patient outcome. In addition, emphasis on personalized medicine and targeted therapies, diagnostics and biomarkers are playing an increasingly important role in drug development. Early adoption of bioinformatics tools can help advance therapeutic candidates.

EPPICon 2017 continues the grand tradition of bringing you the latest advances and opportunities in science and technology.
Get updated on the state of the art in science and business
Form new alliances
Explore investment opportunities

Who Should Attend
Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

OPEN for Registration NOW!!!
Click here to Register

Immuno-Oncology Panel: Chan Whiting, PhD, Aduro Biotech, Robert Sikorski, MD, PhD, Five Prime Therapeutics, Caroline Breitbach, PhD, Turnstone Biologics, Alex Franzusoff, PhD, PACT Pharma
Bioinformatics Keynote Speaker: Nikesh Kotecha, PhD
Bioinformatics Panel:Arshad Ahmad, Ajay Shah, Richard Bourgan, PhD, Genentech
Devices/Diagnostics: Speaker to be announced
Speed Pitch (Please see below for details)

11:30 AM – 1:15 PM: Speed Networking, Vendor Exhibit and Lunch

5:00 PM: Closing Keynote – D. J. Patil, Chief Data Scientist, White House Office of Science and Technology

Evening Reception and Networking
****

CABS, Saturday Afternoon, March 25, 2017

Topic: "Precision Medicine for oncology and immunology"
Date and Time: Saturday March 25, 2017 @ 2:00 pm - 4:00 pm
Location: Hanqi Investment, 1633 Bayshore Hwy, Unit 280, Burlingame, CA 94010
Free
Register at
http://www.cabsweb.org/registration/2455518/Precision%20Medicine%20for%20oncology%20and%20immunology/

Presentations:
1. Liquid biopsies in precision drug development by Shidong Jia, Founder and CEO of Predicine Holdings Ltd.
Cancer immunotherapy and targeted therapy offer great promise in precision oncology, where predictive biomarkers have been extensively investigated in various types of cancer patients. The talk will describe development and clinical application of an innovative, next generation sequencing based liquid biopsy test to support cancer immunotherapy clinical trials.

Speaker Bio
Dr. Shidong Jia is the Founder and CEO of Predicine Holdings Ltd, an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics

and big data in cancer and other serious diseases. The company operates in California, USA and Shanghai, China. Driven by a passion to improve personalized medicine, Dr. Jia has dedicated the past 21 years to basic, translational, and clinical cancer research. His previous work identified p110beta as novel drug target for PTEN-deficient prostate tumors (Jia S, et al. Nature, 2008), a finding that laid the foundation for the clinical development and testing of p110beta inhibitors in cancers. Most recently, his team at Predicine developed world's first ctRNA and ctDNA combined liquid biopsy test for precision medicine in cancer. A former Scientist, principal investigator and prostate cancer disease area lead at Genentech, Dr. Jia spearheaded the biomarker strategies and drug & diagnostics co-developments efforts in support of clinical oncology pipeline at various stages (i.e., early stage research, late stage research, early clinical development, Phase I and Phase II clinical trials), culminated by the Lifecycle Investment Point (LIP) achievement of driving an investigative drug from global Phase II into Phase III pivotal clinical trial. Prior to joining Genentech, Dr. Jia was Laboratory Head for Oncology Drug Discovery at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Jia serves as the Editor-in-Chief of "Journal of Circulating Biomarkers", Guest Associate Editor of "Frontiers in Oncology", and Members of National Cancer Institute Review Committees and the Italian Ministry of Health - Scientific Research and Health Innovation Review Committee. Dr. Jia is a BayHelix member and receipt of several awards, including the "Young Investigator Award" at the Fourth Asian Congress for Microcirculation in Indonesia and the "P.A.R.T. Investigatorship Award" at the Dana-Farber Cancer Institute, Harvard Medical School in Boston.

2. Towards an Assay of Global Immunocompetence by Holden Maecker, Director, Human Immune Monitoring Center, Stanford

A long-term goal of our laboratory is to define metrics of healthy immune function and the deviations that predict or define disease states. There are many facets of the immune system that can be measured, and few clinically accepted tests of immune function. However, we hypothesize that a comprehensive assessment of the proportions, phenotypes, and functions of specific immune cell subsets in blood should be helpful in defining these metrics. We have therefore defined for this purpose a mass cytometry assay using phorbol myristate acetate (PMA)+ionomycin stimulation of peripheral blood mononuclear cells (PBMC), with staining for approximately 40 cell-surface and intracellular proteins, including lineage markers, cytokines, and other functional markers. Mass cytometry, or CyTOF, is a version of flow cytometry that uses heavy metal ion labels in place of fluorochromes, with readout by time-of-flight mass spectrometry. The CyTOF platform allows for many more labeled antibodies to be used in combination, with much less spillover between detection channels, compared to conventional flow cytometry. In this talk, I will describe this methodology and how we are applying it currently to the monitoring of patients undergoing cancer immunotherapy. Our goal in these studies is to better tailor immunotherapies to specific patients, and to suggest approaches that might be useful to address those patients with suboptimal immune function.

Speaker Bio

Dr. Holden T. Maecker received his PhD from Stanford University, is currently Assoc. Prof. at Microbiology & Immunology department and Director of Human Immune Monitoring Center at Stanford. His research is in the area of T cell response signatures and their association with protection from chronic pathogens and cancer. His lab has published a number of papers on this topic, both alone and in collaboration with other groups, in systems such as CMV, HIV, tuberculosis, and cancer. The Human Immune Monitoring Center (HIMC) is a Stanford core service laboratory, which performs blood processing and standardized assays using flow cytometry, genomics, and immunoassay platforms. For the past five years, his lab has gained extensive experience with CyTOF mass cytometry. In addition to being PI on multiple NIH, industry, and foundation grants, Dr. Maecker serves as a core leader for

several cooperative center grants and other large collaborative projects, in which he oversees the use of HIMC assays, including data analysis and interpretation.
****

EPPICon, Saturday, March 25, 2017

Event: EPPICon 2017
Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010

Event Description
The 11th Annual flagship event of EPPIC Global, a San Francisco Bay Area based organization focused on pioneering advances in the life sciences and partnering, mentoring, and networking for professionals.
Featuring talks and panel discussions from leading experts on
Immunotherapy, Bioinformatics and Devices

Who Should Attend
Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

Past Speakers at EPPICon
Kim Bush, Ann Lee, Corey Goodman, Hal Barron, James Sabry, Timothy Moore, Kiran Mazumdar-Shaw, Steven Isaacs and many more…

Stay tuned - Conference registration and additional information coming soon!

EPPICon 2017 Organizing Committee
EPPIC GLOBAL
www.eppicglobal.org
eppic@eppicglobal.org
(408) 357-0601

****

JLABS, Tuesday Morning, March 28, 2017

Topic: "Meet with …MPM Capital"Program Overview:
Speakers: Vinay Bhaskar, Ph.D., Principal with MPM Capital;
Luke Evnin | Managing Director, MPM Capital
Date and Time: Tuesday, March 28, 2017, 10:30 am
Agenda:
10:30am | Registration & Networking
11:00am | Presentation and Q&A
11:45am | Lunch & Networking
12:30-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28. Apply Here.
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,
Fees:
Presentation
$25 | General Public

$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until March 28th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on February 28, 2017. Your application will be reviewed and you will be notified of acceptance by March 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. Registration at https://www.eventbrite.com/e/meet-with-mpm-capital-tickets-29590468889?aff=weekly

Topic Description
Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS (JLABS) with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a $400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fund, a $470M fund that invests solely in oncology companies of any stage (therapeutics only – no diagnostics). For more information on MPM visit http://www.mpmcapital.com/

Vinay Bhaskar, Ph.D., Principal with MPM Capital, will be in attendance to provide an overview presentation on MPM's key areas of interest and venture investment philosophy. Vin will be joined by Luke Evnin to answer any questions and meet with a handful of applicants for one-on-one meetings. To be considered for a one-on-one meeting complete the information required in the link below.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas.

Speaker Bios
Luke Evnin, Ph.D., co-founded MPM with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration

and driving force behind building companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novatris: NVS), Epizyme (EPZM), Idenix (acquired by Merck: MRK), Pacira (PCRX), Pharmasset (acquired by Gilead: GILD) and Radisu (RDUS). MPM believes that these companies are among the biggest successes in biotech history - companies that ultimately resulted in helping thousands of patients live longer with vastly improved lives. Luke was lead investor and has served on the boards of several of MPM's most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira.
Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke's passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in Department of Biochemistry at the University of California - San Francisco. Luke's passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. Luke has devoted significant efforts since 2000 to working with Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Insitiute for Quantitative Gernomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translation Medicine program at UCSF, and Boston University Scleroderma CORT.

Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck, and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation, and diligence for licensing and acquisition opportunities on the Asset Acquisition Team.
Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies and spanned oncology, inflammation and cardio metabolic disease. Through these endeavors, Vin has gained broad expertise across all phases of drug discovery, early development and process sciences. Vin holds a Ph. D. in Biochemistry from UCLA and a B.S. in Biochemistry from UC Davis.

****

Biomedical Engineering Society, Wednesday, March 29, 2017

Event: 8th Annual Bay Area Biomedical Device Conference-Medical Devices in the Connected World
Date and Time: Wednesday, March 29, 2017, 7:30 am
Location: SJSU Student Union Ballroom, San Jose State University
Please take advantage of the reduced early registration which ends on March 16, 2017 at 5:00 pm. PST.
Visit our website at www.biomedconference.org for more details or email info@biomedconference.org if you have any questions.
Register at http://www.biomedconference.org/register

Event Description
The Biomedical Engineering Society at San Jose State University (SJSU) is happy to announce the 8th Annual Bay Area Biomedical Device Conference!
Some exciting features of this conference include:
● An expert biomedical plenary speaker
● Informative parallel sessions
● Interactive Industry & CEO Panels
● Student Research Posters
● Sponsors and representatives from various biomedical companies
● Wine & cheese networking reception
● & More!
****

Bioscience Forum, Wednesday Evening, March 29, 2017

Topic: "Leveraging Biotech's Novel Platforms to Tackle Global Health: A Unique Business Model to Overcome Financial Barriers"
Speaker: Eric Easom,Vice President Neglected Disease R&D, Anacor Pharmaceuticals (Acquired by Pfizer June, 2016)
Date and Time: Wednesday, March 29, 2017, 6:00 PM - 9:00 PM
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Location:The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA
Join us from 6-9 pm to network and hear the latest scientific and business advances in the San Francisco Bay Area biotech community

Event Registration ($3 service fee will apply)
Pre-Registration
$50.00
On-Site Registration
$60.00
Pre-Registration ends Monday, March 27th, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students
Register at http://biosf.org/
Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308
Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, March 23rd
If paying with check, do not complete online registration with Cvent

Topic Description
The world's poorest populations are disproportionately affected by neglected diseases, such as tuberculosis (TB), malaria, visceral leishmaniasis, Chagas disease, human African trypanosomiasis (sleeping sickness), and filarial worms. The current standards of care are difficult to administer, often have significant toxicities, and are increasingly becoming less effective due to the development of resistance. Despite the fact that these diseases cause significant morbidity and mortality worldwide, there has been little investment by industry in developing new therapies due to expectations of low financial returns.

In early disease screenings, Anacor's boron chemistry platform proved to be particularly well-suited for developing treatments for these types of infectious diseases. Though the company felt a responsibility to apply its technology to neglected disease R&D, it was venture-backed and pre-revenue. Devoting time and money to the pursuit of new therapies for complex, unprofitable global health markets could create a conflict with the objectives of its investors. To overcome this, Anacor devised a business plan to leverage non-dilutive funding sources to underwrite this important work. Over the past 10 years, this business model has funded the development of one of the most promising pipelines in this space, with two clinical candidates for African sleeping sickness and TB and the potential for five or more in the next 1-2 years. Over $50 million of funding to subsidize this R&D was raised from non-profits, government agencies, companies and foundations such as the Bill & Melinda Gates Foundation and the Wellcome Trust. Anacor's drug discovery capabilities were supplemented with more than 50 external collaborators from academia, nonprofits and pharmaceutical partners that provided additional expertise in infectious disease biology. Eric will be sharing the story of Anacor's science, its business model, and the strategic value that can be gained from pursuing R&D programs in neglected diseases. The hope is to inspire others by example and demonstrate the depth of potential to treat some of the world's most devastating infectious diseases.

Speaker Bio
Eric is the Vice President for the Neglected Diseases Initiative at Anacor Pharmaceuticals Inc., overseeing the company's research and development efforts to advance new therapeutics for the treatment of neglected diseases. He brings 26 years of pharmaceutical and biotech experience from various leadership roles in R&D program and alliance management, business development, marketing, sales, finance, and manufacturing from his time at Eli Lilly and Company, MedImmune, McKesson, and InteKrin Therapeutics.

Eric Easom served as a member of the Board of Directors at the Infectious Disease Research Institute (IDRI) from 2007-2014 and as Chairman from 2010-2013.

Eric received an MBA from Indiana University and a BS and Masters of Engineering from the University of Louisville.
****

PBSS Workshop, Thursday Afternoon, March 30 2017

Event: "Best CMC Practices for Successful Drug Development and Commercialization: Leveraging QbD and risk-based strategies for efficient CMC development"
Speakers: Prabu Nambiar, Edward Ciolkowski, James Bush (Syner-G Pharma Consulting)
Date and Time: Thursday, March 30, 2017, 12:30-5:00 pm Registration fee (US$): Regular: $125; Academic: $75; For unemployed & students: $25; For vendor-show reps: $25; For major-sponsor rep (incl lunch): $0; For others, details available upon online login.
Location: SF Bay Area: Foster City Crowne Plaza
Registration: http://www.pbss.org/aspx/eventInfo.aspx?eID=528
Further Information:
Registration deadline: 3/28/2017 (it will close sooner if the seating cap is reached)

support@PBSS.org
www.PBSS.org
****

AWIS NCC Workshop, Saturday, April 1, 2017

Workshop: "Leadership by Design: Using Design Thinking to transform your Career"
Workshop Leader: Christopher Ireland
Date and Time: Saturday, April 1st,8:30am-2:00pm

8:30-9:00	Check in and breakfast
9:00-9:15	Opening remarks
9:15-12:00	Leadership by Design
12:00-12:45	Networking lunch
12:45-1:45	Leadership Panel
1:45-2:00	Closing remarks

Location: Genentech, Inc. (View), Room B31-1A, 310 DNA Way, South San Francisco, CA 94080
Registration
http://ebawis.us11.list-manage.com/track/click?u=0bfd730afa47c08495b877f1b&id=2dd81fdafe&e=e5488d3ca3
Sign up for the workshop today!
Fees:
Register for tickets now for a reduced price ($35 for members, $50 for non-members).
http://ebawis.us11.list-manage1.com/track/click?u=0bfd730afa47c08495b877f1b&id=90c3499acb&e=e5488d3ca3

Workshop Description
Do you want to become a successful leader in a fast-paced and rapidly changing work environment? Join us for an interactive workshop on Design Thinking with Christopher Ireland, the coauthor of "Rise of the DEO". Here you will learn a unique perspective on leadership and gain the innovative strategies and skills you need to unleash your inner leader.

Leader Bio
Christopher Ireland worked for 20 years growing and developing Cheskin, a consultancy focused on product and market design innovation. Under her leadership as CEO, the company expanded into global markets, opened four offices, completed two successful mergers and gained a reputation for top quality performance serving a range of high growth clients including Microsoft, Intel, HP, Motorola, Pepsi and more. Christopher and her partners successfully sold Cheskin late in 2007.

Ms. Ireland has an M.B.A. from the Andersen School of Management (UCLA). She currently teaches graduate design students at California College of the Arts in San Francisco and Continuing Studies students at Stanford University. In 2013, she co-authored Rise of the DEO, (New Riders Press) a book examining contemporary leadership traits. She has lectured extensively on the topics of design, human behavior and corporate leadership.

****

QB3, Monday MidDay, April 3, 2017
Topic: "How Federal Politics Impact Funding for Science and Startups"
Speaker: Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC
Date and Time: Monday, April 3, noon to 1:00 pm
Location: Room N-114, Genentech Hall, UCSF Mission Bay

Fee: $10 general admission
Register at https://www.eventbrite.com/e/qb3-seminar-ryan-davison-acs-how-federal-politics-impact-funding-for-science-and-startups-tickets-32633279016?mc_cid=84bb71f0fb&mc_eid=cb4c38a44a

Topic Description
Washington politics usually seem far removed from life at the lab bench. But issues at the federal level can affect what funds the government makes available for grants of all types, from R01 to SBIR. If you understand the ever-changing landscape, you may be able frame your application so it is successful, or expand into research areas that are more likely to get funded. To get the big picture from Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC, join us on April 3. Ryan will provide a general political update, highlight specific pieces of legislation meaningful to researchers, discuss key congressional committees, and explain how Republicans and Democrats view the economy differently. Additionally, Ryan will take a look at SBIR and proof-of-concept funding, and highlight areas likely to get funding in the near future.

Speaker Bio
Dr. Ryan Davison is currently the Manager of Government Affairs at the American Chemical Society where he advocates for legislation that supports the chemical industry. Dr. Davison manages advocacy and policy development on priority issues including manufacturing, tax and trade, intellectual property, patents, biomedical research, innovation and competitiveness, agency funding, and appropriations. Most of his time is spent on Capitol Hill meeting with lawmakers and their staff, attending Congressional hearings and mark-ups, and monitoring bills relevant to the chemical enterprise. Ryan possesses a distinct background of policy and science experience. Before joining the ACS he worked as a policy Fellow at the National Academy of Sciences, served as Biosecurity Analyst at the Federation of American Scientists, was a post-doctoral Fellow at Georgetown University, and an adjunct professor at George Washington University. He holds and Bachelor's and Master's degree in Psychology from Appalachian State University, a Ph.D. in Neuroscience from the University of Alabama at Birmingham (UAB), and is in a unique position to be able to personally highlight the importance of innovation and research to members of Congress and their staff.
****

JLABS, Thursday, April 6, 2017

Event: MedTech Innovator 2017: JLABS Pitch Event
Date and Time: Thursday, April 6, 2017, 9:00 am – 5:00 pm
Agenda:
9:00am - 9:30am | Registration Opens and Networking
9:30am - 10:00am | Welcome & Introduction
10:00am - 12:30pm | Pitch Session (4 companies)
12:30-1:30pm | Networking Lunch
1:30pm - 4:00pm | Pitch Session II (4 companies)
4:00pm - 4:30pm | Success Stories Feature
4:30pm - 5:00pm | Award Presentation
*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.
Location: JLABS @ SSF, 329 Oyster Point Blvd., Floor 3,South San Francisco, CA 94080
Fees: Free

*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.
Apply Now to Pitch at JLABS
The MedTech Innovator SF Pitch Event is opent to all attendees. Startups interested in pitching are encouraged to apply at http://medtechinnovator.org/apply.
See details at https://www.eventbrite.com/e/medtech-innovator-2017-jlabs-pitch-event-tickets-31169197910?aff=weekly

Event Description
About MedTech Innovator 2017
MedTech Innovator is the industry's nonprofit global competition and accelerator. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure and mentorship from the leading players in the medtech industry. In 2017, MedTech Innovator will give out over $500K in cash prizes.

MedTech Innovator Criteria
MedTech Innovator seeks early to mid-stage startups, including medical device, diagnostic, and digital health technologies addressing the following industry-selected themes:

Chronic Disease Management
Cognitive Devices and Platforms
Consumer Healthcare
Healthcare Efficiency and Cost Reduction
Infectious Disease Management
Next-Gen Surgical
Patient Safety and Satisfactio
Population Health; Precision and Personalized Medicine and Technology Enabled Services

Program Participant Benefits
Companies selected to participate in the MedTech Innovator Accelerator receive:
Mentorship from leading investors, manufacturers, providers, payers, IP, regulatory and reimbursement professionals, and others.
Exclusive participation in the three-day MedTech Innovator Accelerator Kick-Off in San Francisco.
A chance to compete onstage for $500,000 in cash prizes and more.

****

WIB, Wednesday Evening, April 12, 2017

Subject: WIB-National Webinar "Risky Business: Mitigating Risk in the Life Sciences"
Speaker: Gretchen Stup, Sr. Consultant at Latham Biopham Group
Date and Time: April 12, 2017, 1:00 p.m. – 2:00 p.m. EST*
*- Please note this webinar's time is listed in Eastern Standard Time.
Pricing Information
Members: Free
Non-Members: $30

* - Registrants will be sent a specific GoToMeeting link to access the webinar. Please be sure to click on the link before the webinar to ensure the program is properly installed on your computer.
Register at http://womeninbio.org/eventdetails.aspx?EventId=30877
Registration Deadline
April 11, 2017
Registrants will receive a webinar link via confirmation email

Webinar Description
Inviting. Supporting. Succeeding.
All projects present risk, and successful project managers recognize that it is vital not to avoid risks, but to understand them. Risk management is the process of identifying, assessing, mitigating, and controlling the known risks in order to increase the probability of meeting your project objectives. By planning for unexpected events, you can be ready to respond if they arise. This webinar will be led by Gretchen Stup, Senior Consultant, Latham BioPharm Group, and will bring to light the importance of Risk Management as well as introduce methods and tools that can be implemented to ensure a successful risk management process. Gretchen will utilize a slide presentation and will review specific examples to help illustrate the key concepts of Risk Management. The presentation will help you understand how to identify what can go wrong, how to assess a risk events probability and impact, and what to do to lessen the probability or impact of a risk event occurring. Real-world examples and considerations from the speaker's professional experience will be highlighted during the webinar. In addition, there will be time allotted for questions and answers at the conclusion of the webinar.
This course will result in up to one hour of PMI-approvable Professional Development Units (PDUs) for the project management field.
Learn more and register for this event.

Speaker Bio
About Gretchen Stup: Gretchen has over 16 years of experience in the management of government contracts, and over 18 total years of experience working in a scientific environment. She is currently a Sr. Consultant at Latham Biopharm Group where she provides program management and systems integration support to government and client related projects. Prior to this, she served as a Sr. Project Manager for DynPort Vaccine Company (DVC) where she managed a >$350 M DoD advanced vaccine development contract and a smaller NIAID R&D contract. She has experience in total project lifecycle management, with a focus on managing and integrating the activities of numerous functional areas, including finance, manufacturing, nonclinical, quality, clinical, and regulatory personnel, and managing project related subcontractors. Prior to working in Program Management, Gretchen co-developed and implemented DVC's comprehensive Risk Management program. She has a Bachelor of Science degree from Shepherd University and is a Project Management Professional (PMP) as certified by the Project Management Institute.
Walk-Ins Accepted?
Walk-ins are not accepted – be sure to register early!
****

JLABS, Tuesday Morning, April 18, 2017

Topic: "Meet with the Gates Foundation"
Speaker: Charlotte Hubbert, PhD | Partner, Gates Foundation Venture Capital
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Date and Time: Tuesday, April 18, 2017, 10:30 am
Agenda:
10:30am | Registration & Networking
11:00am | Company Presentation and Q&A
11:45am | Lunch & Networking
12:45-5:00pm | One-on-one Meetings*

*Companies must have apply ahead of time and be approved for a one-on-one meeting. Application period ends March, 13, 2017. Apply Here.
Fees:
Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 18th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 13, 2017. Your application will be reviewed and you will be notified of acceptance by March 30, 2017. Acceptance of one-pn-one meeting is not guaranteed as all applications must be approved
Registration at https://www.eventbrite.com/e/meet-with-the-gates-foundation-tickets-29533732188?aff=weekly

Program Overview:
The path out of poverty is paved with access to quality healthcare. Do you have solutions that will make a difference? The Bill & Melinda Gates Foundation is advancing science and technology to save lives in developing countries. The Foundation works with partners to deliver proven tools—including vaccines, drugs, and diagnostics—and discover ground breaking new solutions that are affordable and reliable. Focus areas for investments center on infectious diseases including HIV, polio, TB, dengue and malaria, as well as diagnostics and health IT ideas that bring health interventions to people who need them most.
Charlotte Hubbert, Partner with Gates Foundation Venture Capital, will be in attendance to provide an overview presentation on the Foundation's key areas of interest and venture investment philosophy. Gates Foundation Venture Capital operates under the Program Related Investments group at the Bill & Melinda Gates foundation, which manages a $1.5B allocation for private sector investment. Charlotte will be on hand to meet with a handful of applicants one-on-one after the presentation. To be considered for a one-on-one meeting complete the information required at the link below.

Speaker Bio
Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing innovative technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of

development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.
Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stemcells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).
Connect with Charlotte: Connect on LinkedIn

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

****

PBSS Symposium, Monday, April 24, 2017
Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists"
Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)
Date and Time: April 24, 2017, 8:45-17:00
Location: Crowne Plaza, Foster City, CA
Registration fee (USD): Minisymposium fee: $195;
Registration: http://www.PBSS.org
Registration deadline:4/20/2017 (it will close sooner if the seating cap is reached)

Topic Description
Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

Tentative topics and speakers:
Morning: 8:45-12:00

Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech
Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS
Sponsor presentation
Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck
Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00
Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech
Sponsor presentation
Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech
Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid off target hepatotoxicity - Raju Subramanian, Gilead
Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech
Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen
****

JLABS Bay Area, Tuesday Mid Day, May 2, 2017

Topic: "Money Matters - Insider Tips on Raising Money"
Speaker: Julie Papanek, Partner, Canaan Partners
Date and Time: Tuesday, May 2, 2017, 10:30 am – 1:00 pm
Agenda:
10:30 AM | Registration and Networking
11:00 AM | Presentation
11:30 AM | Q&A
12:00 PM | Food and Networking
1:00 PM | Program Close
Fees:
$25 | General Public
$15 | Student
$45 | At the door
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor,South San Francisco, California
Order at https://www.eventbrite.com/e/money-matters-insider-tips-on-raising-money-tickets-32167293240?aff=weekly

Speakers Bio
Julie Papanek is a Partner at Canaan Partners where she concentrates on biopharmaceutical, digital health and consumer medical device investments. Julie currently sits on the board of Protagonist Therapeutics (PTGX) and has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development.

Julie earned her MBA from Stanford¹s Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.

****

JLABS, Tuesday Morning, May 23, 2017

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"
Speakers:
Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
William J. Newell | CEO, Sutro Biopharma
Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Fees:
$25 | General Public
$15 | Student
Order at https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly

Event Details
How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk with provide real world examples and focus on the following topics:
Intro to Collaboration Agreements / General provisions
Statement of objectives/work
Budget
IP
Restrictions and opportunities created by agreements
Real world examples from panel members
The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup
Guests will be provided supporting materials including:
Key provisions guide

Sample Collaboration agreements
This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to…Workshop" is informal and interactive so bring your questions with you!

Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.
Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.
Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to

participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
****